Abiraterone Plus Prednisone Added to ADT and Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Lancet 2022 Apr 08;[EPub Ahead of Print], K Fizazi, S Foulon, J Carles, G Roubaud, R McDermott, A Fléchon, B Tombal, S Supiot, D Berthold, P Ronchin, G Kacso, G Gravis, F Calabro, JF Berdah, A Hasbini, M Silva, A Thiery-Vuillemin, I Latorzeff, L Mourey, B Laguerre, S Abadie-Lacourtoisie, E Martin, C El Kouri, A Escande, A Rosello, N Magne, F Schlurmann, F Priou, ME Chand-Fouche, SV Freixa, M Jamaluddin, I Rieger, A BossiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.